4C5 CD3d receptor CR2 (CD21)
- Known as:
- 4C5 CD3d receptor CR2 (CD21)
- Catalog number:
- mc-869
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Kamiya biomedical company
- Gene target:
- 4C5 CD3d receptor CR2 (CD21)
Related genes to: 4C5 CD3d receptor CR2 (CD21)
- Gene:
- CD3D NIH gene
- Name:
- CD3d molecule
- Previous symbol:
- T3D
- Synonyms:
- -
- Chromosome:
- 11q23.3
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2019-04-23
- Gene:
- CR2 NIH gene
- Name:
- complement C3d receptor 2
- Previous symbol:
- -
- Synonyms:
- CD21, C3DR
- Chromosome:
- 1q32.2
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2019-04-23
- Gene:
- IL10RA NIH gene
- Name:
- interleukin 10 receptor subunit alpha
- Previous symbol:
- IL10R
- Synonyms:
- HIL-10R, CDW210A, CD210a, CD210
- Chromosome:
- 11q23.3
- Locus Type:
- gene with protein product
- Date approved:
- 1994-05-12
- Date modifiied:
- 2019-04-23
- Gene:
- IL12RB1 NIH gene
- Name:
- interleukin 12 receptor subunit beta 1
- Previous symbol:
- IL12RB
- Synonyms:
- CD212
- Chromosome:
- 19p13.11
- Locus Type:
- gene with protein product
- Date approved:
- 1995-09-14
- Date modifiied:
- 2019-04-23
- Gene:
- IL13RA1 NIH gene
- Name:
- interleukin 13 receptor subunit alpha 1
- Previous symbol:
- -
- Synonyms:
- IL-13Ra, NR4, CD213a1
- Chromosome:
- Xq24
- Locus Type:
- gene with protein product
- Date approved:
- 1998-03-26
- Date modifiied:
- 2015-12-11
Related products to: 4C5 CD3d receptor CR2 (CD21)
"Recombinant Human Interleukin-18 receptor accessory protein_IL18RAP ""Recombinant Human Interleukin-18 receptor accessory protein_IL18RAP ""Recombinant Human Interleukin-18 receptor accessory protein_IL18RAP ""Recombinant Human Interleukin-18 receptor accessory protein_IL18RAP ""Recombinant Human Interleukin-18 receptor accessory protein_IL18RAP""Recombinant Human Interleukin-18 receptor accessory protein_IL18RAP""Recombinant Human Interleukin-18 receptor accessory protein_IL18RAP""Recombinant Human Interleukin-18 receptor accessory protein_IL18RAP"(Ala1)-PAR-4 (1-6) (mouse)
(Ala1)-Thrombin Receptor-Like 3 (1-6) (mouse), (Ala1)-Proteinase Activated Receptor 4 (1-6) (mouse), (Ala1)-Coagulation Factor II Receptor-Like 3 (1-6) (mouse), AYPGKF 98%(Ala1)-PAR-4 (1-6) amide (mouse)
AYPGKFamide, (Ala1)-Thrombin Receptor-Like 3 (1-6) amide (mouse), (Ala1)-Coagulation Factor II Receptor-Like 3 (1-6) amide (mouse), (Ala1)-Proteinase Activated Recepto(Ala1)_PAR_4 (1_6) (mouse) Salt Trifluoroacetate Binding _ Synonym (Ala1)_Thrombin Receptor_Like 3 (1_6) (mouse), (Ala1)_Proteinase Activated Receptor 4 (1_6) (mouse), (Ala1)_Coagulation Factor II(Ala1)_PAR_4 (1_6) (mouse) Salt Trifluoroacetate Binding _ Synonym (Ala1)_Thrombin Receptor_Like 3 (1_6) (mouse), (Ala1)_Proteinase Activated Receptor 4 (1_6) (mouse), (Ala1)_Coagulation Factor II(Ala1)_PAR_4 (1_6) (mouse) Salt Trifluoroacetate Binding _ Synonym (Ala1)_Thrombin Receptor_Like 3 (1_6) (mouse), (Ala1)_Proteinase Activated Receptor 4 (1_6) (mouse), (Ala1)_Coagulation Factor II(Ala1)_PAR_4 (1_6) (mouse) Salt Trifluoroacetate Binding _ Synonym (Ala1)_Thrombin Receptor_Like 3 (1_6) (mouse), (Ala1)_Proteinase Activated Receptor 4 (1_6) (mouse), (Ala1)_Coagulation Factor II(Ala1)_PAR_4 (1_6) (mouse) Salt Trifluoroacetate Binding _ Synonym (Ala1)_Thrombin Receptor_Like 3 (1_6) (mouse), (Ala1)_Proteinase Activated Receptor 4 (1_6) (mouse), (Ala1)_Coagulation Factor II Related articles to: 4C5 CD3d receptor CR2 (CD21)
- Bladder cancer (BLCA) exhibits a poor prognosis, highlighting the urgent need for reliable prognostic genes. Although succinylation is linked to tumor progression, its role in BLCA remains understudied. This study aimed to identify and validate prognostic succinylation-related genes (SRGs) in BLCA and elucidate their impact on the tumor microenvironment (TME). - Source: PubMed
Publication date: 2026/05/15
Yang JiajianYou ZhengyaoMo HaojiePu JinxianShen GangMiao Zhijun - Severe combined immune deficiency (SCID) is a rare inherited defect of lymphocytes causing life-threatening opportunistic infections in early infancy. Data on SCID from China are limited. This study explores the clinical, immunologic, and genetic features of a SCID cohort from Yunnan Province in China and reports novel variants. We collated clinical, laboratory, and molecular details from patients with a clinical profile suggestive of SCID. Trio-based whole-exome sequencing was performed to identify genetic variants. For the 9 previously reported variants identified in our cohort, we systematically reviewed the literature for additional cases carrying the same variants and compared clinical and immunologic features. Eleven infant patients (8 males and 3 females) were included. Molecular diagnoses were obtained in 10 patients, as follows: IL2RG (3), RAG2 (3), LIG4 (2), DCLRE1C (1), and CD3D (1). Nine patients presented with classic SCID features within the first 3 months of life. Eleven variants were identified: 2 novel RAG2 variants (p.L469P and p.Q492R) and 9 variants previously reported in SCID-associated genes. One patient with the p.Q492R variant exhibited a relatively milder clinical course. An extremely rare case of Omenn syndrome due to IL2RG deficiency was also observed. Ten of 11 patients died within 6 months of age. The literature review identified 94 additional cases carrying these same variants; clinical presentations were generally consistent with our patients, although some variability was observed. We characterized the clinical and genetic profiles of 11 SCID patients from Yunnan, China, identifying two novel RAG2 variants. While these findings expand the mutational spectrum in understudied populations, the high mortality and diagnostic delays observed here underscore the critical need for universal newborn screening in China. Further functional studies are required to confirm the impact of the identified variants. - Source: PubMed
Publication date: 2026/05/28
Wang YanjunJin RuohongHan QianHang LingLv LingChen GuizhiHu RongXiao Shufang - Breast cancer is a prevalent malignancy among women worldwide. Understanding its molecular mechanisms is crucial for prevention, early diagnosis, and treatment. Using a dataset of intraoperative radiotherapy (IORT) for breast cancer, we analyzed 21 breast tissue samples from patients who received IORT and 16 samples from those who did not. Principal component analysis was employed to reveal data structure, and differentially expressed genes (DEGs) were identified. We constructed a gene network using weighted gene co-expression network analysis and conducted functional enrichment analysis and gene set enrichment analysis. Immune infiltration analysis and protein-protein interaction network analysis were performed, resulting in gene expression heatmaps and Comparative Toxicogenomics Database analysis. Finally, regulatory microRNAs (miRNA) for core genes were predicted using miRNA prediction websites. A total of 2774 DEGs were identified. Principal component analysis demonstrated the differentiation between IORT and non-IORT samples. DEGs were enriched in key biological processes, such as T-cell receptor signaling, immunological synapse formation, and apoptosis. Gene set enrichment analysis validated the functional enrichment of DEGs. Weighted gene co-expression network analysis constructed 15 modules and identified hub genes. Protein-protein interaction network analysis revealed 4 core genes (CD2, CD3D, CD3G, and CD3E). miRNA prediction identified regulatory miRNAs for these core genes. Comparative Toxicogenomics Database analysis revealed that these core genes are associated with breast tumors and inflammation. Immune infiltration analysis showed a high proportion of Macrophages M0 and Macrophages M2 in the samples and revealed correlations between T cells and neutrophils. These findings suggest that the core genes may play key roles in the pathological changes and immune regulation of breast cancer tissues. CD2 and CD3D may serve as potential immune-related biomarkers for IORT in the treatment of breast cancer, influencing tissue pathological changes in breast cancer patients by regulating immune responses and cell signaling pathways. - Source: PubMed
Li ShenglanFu YubingZhang Huiying - The extracellular matrix (ECM) plays a critical role in the tumor microenvironment (TME). However, the prognostic relevance of matrisome-related genes (MRGs) in bladder cancer (BLCA) remains poorly understood. This study aimed to establish a matrisome-related gene signature for prognostic stratification in bladder cancer and to further characterize its associations with tumor microenvironmental features and candidate compounds. - Source: PubMed
Publication date: 2026/04/20
Wu GongpingYu WeitaoYao DongnuanMa XuemingFan ChengweiHou JuanjuanRen XuezhaoTian Junqiang - Compared with transplanted tumors, autochthonous tumors are difficult to cure using experimental radiation therapy in mice. Here we analyzed differences in immune-related gene expression profiles between mouse fibrosarcomas subcutaneously induced by 3-methylcholanthrene (3MC) and their corresponding transplanted tumors. The immune genes examined were Pd1, Pdl1, Pdl2, Cd3d, Cd8a, Cd8b, Ifnγ, Itga2, Gzmb, and Foxp3. Among 12 tumors, one was non-transplantable and showed a benign phenotype with an abundance of DX5+ natural killer cells and CD8+ T cells together with increased IFNγ expression and mRNA levels of all immune genes except for Itga2. The other 11 transplantable tumors showed increased expression of Pd1, Pdl1, Pdl2, Cd3d, Cd8b, and Ifnγ following transplantation into syngeneic mice. These effects of transplantation highlight the relevance of immune gene expression status to the curability of tumors. - Source: PubMed
Publication date: 2026/04/24
Tanooka HiroshiKudo-Saito ChieChiwaki FumikoIshiai MasamichiTatsumi KouichiSasaki HirokiOchiya Takahiro